两大赛道争先！公募最新业绩排名出炉

Group 1 - The overall performance of equity funds in April was poor, with sectors like consumer electronics and photovoltaic experiencing significant declines, negatively impacting related thematic fund performance [1][6] - Innovative pharmaceutical stocks, particularly innovative drug funds, showed a strong rebound in April, standing out among thematic funds [1][7] - The robotics sector saw a significant recovery in fund net values, demonstrating a "V-shaped" recovery by the end of April [1][8] Group 2 - A number of innovative drug thematic funds surged to the top of performance rankings, with the Huatai-PineBridge Hong Kong Advantage Select fund briefly leading the year-to-date performance [2][7] - The overall net value of equity funds decreased in April, while pure bond funds continued to recover, with some reaching new highs [2][10] - The performance of thematic funds varied greatly, with some sectors like artificial intelligence and photovoltaic lagging behind [8][9] Group 3 - The top-performing funds year-to-date included the Penghua Carbon Neutrality Theme A fund, which achieved a return of 64.87%, and the Huatai-PineBridge Hong Kong Advantage Select A fund, with a return of 59.77% [4] - Many innovative drug funds have seen returns exceeding 40% year-to-date, indicating a significant recovery after several years of decline [7][8] - The bond market showed signs of stabilization in April, with nearly 90% of pure bond funds achieving positive returns year-to-date [11]